155 related articles for article (PubMed ID: 17803984)
1. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis.
Ieko M; Nakabayashi T; Tarumi T; Naito S; Yoshida M; Kanazawa K; Mizukami K; Koike T
Clin Chim Acta; 2007; 386(1-2):38-45. PubMed ID: 17803984
[TBL] [Abstract][Full Text] [Related]
2. [Molecular marker for detecting hypercoagulable state].
Magari Y; Mizunaga S; Ito M; Shibata T; Ito H
Rinsho Byori; 1994 Jan; 42(1):22-33. PubMed ID: 8107279
[TBL] [Abstract][Full Text] [Related]
3. [Differentiation of fibrinolysis and fibrinogenolysis by analysis of FDP fragments].
Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
Rinsho Byori; 1992 Jul; 40(7):789-94. PubMed ID: 1507499
[TBL] [Abstract][Full Text] [Related]
4. [Studies on the fragments of FDP in 3 patients with DIC associated with acute promyelocytic leukemia].
Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
Rinsho Byori; 1993 Jun; 41(6):719-25. PubMed ID: 8361040
[TBL] [Abstract][Full Text] [Related]
5. [Study on cases of D dimer values were dissociated from FDP-E].
Himizu M; Ishii K; Katagiri H; Saga K; Ono F; Yamamoto M; Todoroki T; Kawai Y; Watanabe K; Iri H
Rinsho Byori; 1991 Mar; 39(3):302-8. PubMed ID: 2051606
[TBL] [Abstract][Full Text] [Related]
6. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review.
Nieuwenhuizen W
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):93-6. PubMed ID: 8457659
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of cross linked fibrin degradation products in thrombotic disorders].
Koyama T; Oura Y; Higuchi M; Kakishita E; Nagai K
Rinsho Ketsueki; 1989 May; 30(5):659-62. PubMed ID: 2677436
[TBL] [Abstract][Full Text] [Related]
8. [Fibrin monomer assay].
Kobayashi H; Matsuo M; Ikeguchi K; Yamamoto K; Kario K; Matsuo T
Rinsho Byori; 1991 Jul; 39(7):689-93. PubMed ID: 1920860
[TBL] [Abstract][Full Text] [Related]
9. [Studies on the fragments of FDP in 4 patients with DIC].
Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
Rinsho Byori; 1992 Oct; 40(10):1089-95. PubMed ID: 1307614
[TBL] [Abstract][Full Text] [Related]
10. [Studies on the fragments of FDP in 3 non-DIC patients with increased FDP levels in the sera].
Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Shinoda T; Nakahata T; Saitoh H
Rinsho Byori; 1993 Feb; 41(2):220-6. PubMed ID: 8361025
[TBL] [Abstract][Full Text] [Related]
11. Use of the fibrin D-dimer in screening for coagulation abnormalities in preeclampsia.
Trofatter KF; Howell ML; Greenberg CS; Hage ML
Obstet Gynecol; 1989 Mar; 73(3 Pt 1):435-40. PubMed ID: 2915868
[TBL] [Abstract][Full Text] [Related]
12. Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases.
Shibata T; Magari Y; Kamberi P; Ishii T; Tomo T; Yasumori R; Nasu M
Clin Nephrol; 1995 Aug; 44(2):91-5. PubMed ID: 8529315
[TBL] [Abstract][Full Text] [Related]
13. [Differentiation between fibrin degradation products and fibrinogen degradation products by using newly developed ELISAs].
Isogai N; Yamagishi T; Kaku M; Matsumoto K; Yamamoto Y; Kuroso K; Arai M; Yorifuji H; Fukutake K; Fujimaki M
Rinsho Byori; 1991 Jul; 39(7):753-7. PubMed ID: 1920869
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M
Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722
[TBL] [Abstract][Full Text] [Related]
15. [Persistent discrepancy between FDP and D-dimer in a patient with acute leukemia].
Sato N; Takahashi H; Nikuni K; Seki Y; Wada K; Tatewaki W; Shibata A
Rinsho Ketsueki; 1995 Mar; 36(3):212-7. PubMed ID: 7783324
[TBL] [Abstract][Full Text] [Related]
16. Biological behavior of higher molecular weight products of fibrinolysis.
Chang ML; Bang NU
J Lab Clin Med; 1977 Jul; 90(1):216-26. PubMed ID: 874368
[TBL] [Abstract][Full Text] [Related]
17. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Carroll RC; Lockhart MS; Taylor FB
J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of fibrinogen degradation products.
Bick RL
Semin Thromb Hemost; 1982 Oct; 8(4):302-30. PubMed ID: 6758120
[No Abstract] [Full Text] [Related]
19. [Study of hemostatic molecular marker].
Wada H; Ioka M
Rinsho Byori; 1997 Apr; 45(4):310-4. PubMed ID: 9136593
[TBL] [Abstract][Full Text] [Related]
20. A simple rapid method for isolating soluble fibrin complexes from fibrinogen by treatment with thrombin and t-AMCHA.
Hayashi S; Yamada K
Thromb Haemost; 1980 Feb; 42(5):1388-97. PubMed ID: 6154323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
